Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/82596
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Clinical and angiographic results with the next-generation resolute stent system A prospective, multicenter, first-in-human trial
Author: Meredith, I.
Worthley, S.
Whitbourn, R.
Walters, D.
McClean, D.
Horrigan, M.
Popma, J.
Cutlip, D.
DePaoli, A.
Negoita, M.
Fitzgerald, P.
Citation: JACC: Cardiovascular Interventions, 2009; 2(10):977-985
Publisher: Elsevier Inc.
Issue Date: 2009
ISSN: 1936-8798
1876-7605
Statement of
Responsibility: 
Ian T. Meredith, Stephen Worthley, Robert Whitbourn, Darren L. Walters, Dougal McClean, Mark Horrigan, Jeffrey J. Popma, Donald E. Cutlip, Ann DePaoli, Manuela Negoita, Peter J. Fitzgerald, for the RESOLUTE Investigators
Abstract: <h4>Objectives</h4>The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular Inc., Santa Rosa, California).<h4>Background</h4>Revascularization benefits associated with current drug-eluting stents are often diminished in the presence of complex coronary lesions and in certain patient cohorts. Resolute uses a new proprietary polymer coating that extends the duration of drug delivery to match the longer healing duration often experienced in more complex cases.<h4>Methods</h4>The RESOLUTE trial was a prospective, nonrandomized, multicenter study of the Resolute stent in 139 patients with de novo coronary lesions with reference vessel diameters > or =2.5 and < or =3.5 mm and lesion length > or =14 and < or =27 mm. The primary end point was 9-month in-stent late lumen loss by quantitative coronary angiography. Secondary end points included major adverse cardiac events (MACE) at 30 days, 6, 9, and 12 months; acute device, lesion, and procedure success; and 9-month target vessel failure (TVF), target lesion revascularization (TLR), stent thrombosis, neointimal hyperplastic (NIH) volume, and percent NIH volume obstruction.<h4>Results</h4>The 9-month in-stent late lumen loss was 0.22 +/- 0.27 mm. Cumulative MACE were 4.3%, 4.3%, 7.2%, and 8.7% at 30 days, 6, 9, and 12 months, respectively. Acute lesion, procedure, and device success rates were 100.0%, 95.7%, and 99.3%, respectively. At 9 months, TLR was 0.0%, TVF was 6.5%, stent thrombosis was 0.0%, NIH volume was 6.55 +/- 7.83 mm(3), and percent NIH volume obstruction was 3.73 +/- 4.05%.<h4>Conclusions</h4>In this feasibility study, the Resolute stent demonstrated low in-stent late lumen loss, minimal neointimal hyperplastic ingrowth, low TLR, no stent thrombosis, and acceptable TVF and MACE. (The RESOLUTE Clinical Trial; NCT00248079).
Keywords: coronary artery disease
drug-eluting stents
zotarolimus
Rights: ©2009 By the American College of Cardiology Foundation
DOI: 10.1016/j.jcin.2009.07.007
Published version: http://dx.doi.org/10.1016/j.jcin.2009.07.007
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.